Concord Biotech Limited announced that its Board has approved a modified list of Key Managerial Personnel (KMP). This updated list is critical for determining the materiality of future events and ensuring proper disclosures are made to the Stock Exchanges. The document names four key individuals, including the Chairman and Managing Director, the Joint Managing Director and CEO, the CFO, and the Company Secretary.
Board Action on KMP Disclosure Framework
Concord Biotech Limited has formally communicated an update regarding its internal governance structure for external reporting. Pursuant to regulatory requirements, the Board of Directors has approved a modified list of Key Managerial Personnel (KMP). This list is specifically designated for the purpose of assessing the materiality of any event or information that requires disclosure to the stock exchanges.
Designated Key Managerial Personnel
The approved list, effective as of the announcement date of February 11, 2026, identifies the following four executives responsible for such disclosures:
- Mr. Sudhir Vaid: Serving as the Chairman and Managing Director.
- Mr. Ankur Vaid: Holding the roles of Joint Managing Director and Chief Executive Officer.
- Mr. Raviraj Karia: Designated as the Chief Financial Officer (CFO).
- Mr. Paritosh Trivedi: The Company Secretary and Compliance Officer.
Authority for Disclosure
The communication, signed by Mr. Sudhir Vaid, Chairman & Managing Director, confirms that these individuals, detailed along with their contact information, are authorized to handle the necessary regulatory filings regarding material events going forward. The document was digitally signed on February 11, 2026.
Source: BSE
